Palmitoylethanolamide
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
This article is a stub. |
Palmitoylethanolamide or PEA is a naturally occurring fatty acid that is available as a supplement.[1][2][3] PEA is also known as palmidrol.[3]
Theory[edit | edit source]
Evidence[edit | edit source]
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Available over the counter.
Notable studies[edit | edit source]
- 2012, New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide [1]
- 2002, The Palmitoylethanolamide Family: A New Class of Anti-Inflammatory Agents?[2]
- 2009, The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review[4] (Full text)
- 2014, Palmitoylethanolamide in CNS health and disease[5] (Abstract)
See also[edit | edit source]
Learn more[edit | edit source]
- Palmitoylethanolamide (PEA) - WebMD
- Hesselink
References[edit | edit source]
- ↑ 1.0 1.1 http://dx.doi.org/10.2174/1876386301205010012
- ↑ 2.0 2.1 https://www.ingentaconnect.com/content/ben/cmc/2002/00000009/00000006/art00003
- ↑ 3.0 3.1 https://www.webmd.com/vitamins/ai/ingredientmono-1596/palmitoylethanolamide-pea
- ↑ https://journals.sagepub.com/doi/abs/10.1177/1049909119850807
- ↑ https://pubmed.ncbi.nlm.nih.gov/24844438/